Tandem Diabetes Care INC Form 4 insider transactions

Tandem Diabetes Care's EVP & Chief Commercial Officer, Mark Novara, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Tandem Diabetes Care CEO John F. Sheridan reported the vesting of restricted stock units and associated tax withholdings, increasing his direct beneficial ownership of common stock.

Tandem Diabetes Care Inc.'s EVP and CFO, Leigh Vosseller, converted restricted stock units into common stock and had shares withheld for tax obligations.

Tandem Diabetes Care's EVP & Chief Legal Officer, Shannon Marie Hansen, reported the exercise of restricted stock units and subsequent tax-related share withholdings.

Tandem Diabetes Care Inc.'s EVP & COO, Jean-Claude Kyrillos, reported the vesting of 3,636 restricted stock units and the withholding of 2,118 shares for tax obligations.

Tandem Diabetes Care's EVP & Chief Commercial Officer, Mark Novara, reported a future vesting of 7,415 restricted stock units and subsequent tax withholding on December 15, 2025.

Tandem Diabetes Care's Chief Technology Officer, Rick Carpenter, reported the vesting of 406 restricted stock units and subsequent withholding of 207 shares for tax obligations.

Tandem Diabetes Care EVP and Chief Strategy Officer, Elizabeth Gasser, transferred 3,000 shares of common stock from her direct holdings to The Gasser Family Trust.

Tandem Diabetes Care Director Sandra Beaver received an award of 20,242 Restricted Stock Units under the company's 2023 Long-Term Incentive Plan.

Susan Morrison, EVP & Chief Admin. Officer at Tandem Diabetes Care, converted restricted stock units into common stock and had shares withheld for tax obligations.

Tandem Diabetes Care Inc. CEO John F. Sheridan reported the vesting and exercise of restricted stock units, resulting in a net increase in his direct beneficial ownership of common stock.

Elizabeth Anne Gasser, EVP and Chief Strategy Officer at Tandem Diabetes Care Inc., increased her direct beneficial ownership through ESPP purchases and RSU vesting, while also having shares withheld for tax obligations.

Tandem Diabetes Care Inc.'s Chief Technology Officer, Rick Carpenter, reported multiple transactions including stock acquisitions through an employee plan and RSU vesting, alongside tax-related share dispositions.

Mark D. Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care, reported the vesting of restricted stock units and subsequent tax withholding.

Tandem Diabetes Care's EVP & COO, Jean-Claude Kyrillos, acquired 160 shares of common stock through the company's Employee Stock Purchase Plan.

Tandem Diabetes Care Inc.'s EVP & CFO, Leigh Vosseller, reported pre-scheduled vesting of restricted stock units and associated tax withholdings under a Rule 10b5-1 plan, resulting in a net increase in direct common stock ownership.

Shannon Marie Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care, reported recent acquisitions of common stock through an ESPP and RSU vestings, alongside tax-related dispositions.

Tandem Diabetes Care's EVP & COO, Jean-Claude Kyrillos, reported the vesting of 3,636 restricted stock units and the withholding of 1,301 shares for tax obligations.

Tandem Diabetes Care's Chief Technology Officer, Rick Carpenter, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Tandem Diabetes Care's EVP & Chief Commercial Officer, Mark Novara, reported a future transaction involving the vesting of 7,415 Restricted Stock Units and the withholding of shares for tax obligations.

Tandem Diabetes Care's EVP & Chief Commercial Officer, Mark Novara, reported the vesting of 76 restricted stock units and the withholding of 40 shares for tax purposes.

Tandem Diabetes Care's EVP & Chief Administrative Officer, Susan Morrison, acquired common stock through RSU vesting and disposed of shares for tax obligations.

Tandem Diabetes Care CEO John F. Sheridan increased his direct beneficial ownership of common stock by 5,636 shares through the vesting of restricted stock units and associated tax withholdings.

Tandem Diabetes Care's Chief Technology Officer, Rick Carpenter, reported routine acquisitions of common stock through restricted stock unit vesting and corresponding tax-related dispositions.

Tandem Diabetes Care Inc.'s EVP and CFO, Leigh Vosseller, reported future acquisitions of common stock through Restricted Stock Unit vesting and subsequent tax-related dispositions.

Tandem Diabetes Care's EVP & Chief Legal Officer reported routine stock acquisitions and dispositions related to Restricted Stock Unit vesting.

Tandem Diabetes Care's Chief Strategy Officer, Elizabeth Gasser, reported the vesting of restricted stock units and associated tax withholdings.

Tandem Diabetes Care Inc.'s President and CEO, John F. Sheridan, acquired 10,000 shares of common stock, signaling strong insider confidence.

Tandem Diabetes Care's EVP & CFO, Leigh Vosseller, acquired 13,720 shares of common stock at an average price of $10.8895 per share.

Tandem Diabetes Care's EVP & Chief Operating Officer, Jean-Claude Kyrillos, acquired 14,545 shares of common stock through the vesting of restricted stock units, with a portion withheld for tax obligations.